All In Biotech

Drug Trial Radar · NCT00589303

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

Pacing and AV Node Ablation Compared to Drug Therapy in Symptomatic Elderly Patients With Atrial Fibrillation Clinical Trial (PACIFIC) - Pilot Study

Last checked: Nov 19, 2026Latest source record: Apr 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

27

Actual

Start

Dec 2007

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic
First posted
Jan 9, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF).

Conditions

  • Atrial Fibrillation
  • Heart Failure

Interventions

  • FDA approved rate and rhythm control drugsDrug

    Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion. Rate Control: Beta-Blocker: * metoprolol * atenolol * carvedilol Calcium Channel Blocker: * verapamil * diltiazem Rhythm Control: * procainamide * quinidine * disopyramide * propafenone * flecainide * sotalol * dofetilide * amiodarone

  • AV Node ablation and device implantDevice

    Pacing Systems: * Enpusle Premarket Approval Number (PMA#) P980035 * EnRhythm PMA# P980035 * Adapta PMA# P980035 Cardiac Resynchronization Therapy (CRT) Pacing Systems: \- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031 Implantable Cardioverter-Defibrillator (ICD) Pacing Systems: * EnTrust PMA# P980016 * Virtuoso PMA# P980016 ICD CRT Pacing Systems: * InSync Maximo PMA# P980016 * InSync Sentry PMA# P890003 * Concerto PMA# P980016

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cardiac Hospitalization Within Six Months of EnrollmentTime frame: Six months after enrollment

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • The Heart Group

    Evansville, Indiana

  • Mayo Clinic

    Rochester, Minnesota

  • Oregon Health and Science University

    Portland, Oregon

  • Chattanooga Heart Institute

    Chattanooga, Tennessee

  • University of Calgary and Calgary Health Region

    Calgary, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.